Literature DB >> 12163261

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.

Andrea Jegerlehner1, Alain Tissot, Franziska Lechner, Peter Sebbel, Iris Erdmann, Thomas Kündig, Thomas Bächi, Tazio Storni, Gary Jennings, Paul Pumpens, Wolfgang A Renner, Martin F Bachmann.   

Abstract

Virus like particles (VLPs) are known to induce potent B cell responses in the absence of adjuvants. Moreover, epitope-specific antibody responses may be induced by VLPs that contain peptides inserted in their immunodominant regions. However, due to steric problems, the size of the peptides capable of being incorporated into VLPs while still permitting capsid assembly, is rather limited. While peptides genetically fused to either the N- or C-terminus of VLPs present fewer assembly problems, the immune responses obtained against such epitopes are often limited, most likely because the epitopes are not optimally exposed. In addition, such particles may be less stable in vivo. Here, we show that peptides and proteins engineered to contain a free cys can be chemically coupled to VLPs formed from the hepatitis B core antigen (HBcAg) containing a lys in the immuno-dominant region. By using this approach steric hindrance of capsid assembly is abrogated. Peptides or protein coupled to VLPs in an oriented fashion are shown to induce strong and protective B cell responses even against self-epitopes in the absence of adjuvants. This molecular assembly system may be used to induce strong B cell responses against most antigens. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163261     DOI: 10.1016/s0264-410x(02)00266-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  67 in total

1.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.

Authors:  Jean-Noel Billaud; Darrell Peterson; Byung O Lee; Toshiyuki Maruyama; Antony Chen; Matti Sallberg; Fermin Garduño; Phillip Goldstein; Janice Hughes; Joyce Jones; David Milich
Journal:  Vaccine       Date:  2006-11-17       Impact factor: 3.641

3.  Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation.

Authors:  Franziska Zabel; Antonia Fettelschoss; Monique Vogel; Pål Johansen; Thomas M Kündig; Martin F Bachmann
Journal:  Immunology       Date:  2017-01-05       Impact factor: 7.397

4.  The method of noncovalent in vitro binding of target proteins to virus-like nanoparticles formed by core antigen of hepatitis B virus.

Authors:  E A Blokhina; V V Kupriyanov; N V Ravin; K G Skryabin
Journal:  Dokl Biochem Biophys       Date:  2013-03-13       Impact factor: 0.788

5.  Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.

Authors:  Hong Zheng; Yun Hu; Wei Huang; Sabina de Villiers; Paul Pentel; Jianfei Zhang; Harry Dorn; Marion Ehrich; Chenming Zhang
Journal:  J Biomed Nanotechnol       Date:  2015-12       Impact factor: 4.099

6.  Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Authors:  Juan Carlos Almagro; Gary L Gilliland; Felix Breden; Jamie K Scott; Devin Sok; Matthias Pauthner; Janice M Reichert; Gustavo Helguera; Raiees Andrabi; Robert Mabry; Mathieu Bléry; James E Voss; Juha Laurén; Lubna Abuqayyas; Stefan Barghorn; Eshel Ben-Jacob; James E Crowe; James S Huston; Stephen Albert Johnston; Eric Krauland; Fridtjof Lund-Johansen; Wayne A Marasco; Paul W H I Parren; Kai Y Xu
Journal:  MAbs       Date:  2014-03-03       Impact factor: 5.857

7.  Versatile virus-like particle carrier for epitope based vaccines.

Authors:  Alain C Tissot; Regina Renhofa; Nicole Schmitz; Indulis Cielens; Edwin Meijerink; Velta Ose; Gary T Jennings; Philippe Saudan; Paul Pumpens; Martin F Bachmann
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

8.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.

Authors:  Nicole Schmitz; Klaus Dietmeier; Monika Bauer; Melanie Maudrich; Stefan Utzinger; Simone Muntwiler; Philippe Saudan; Martin F Bachmann
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

9.  Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.

Authors:  Graeme E Price; Mark R Soboleski; Chia-Yun Lo; Julia A Misplon; Mary R Quirion; Katherine V Houser; Melissa B Pearce; Claudia Pappas; Terrence M Tumpey; Suzanne L Epstein
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

10.  Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Authors:  Mitchell Tyler; Ebenezer Tumban; Agnieszka Dziduszko; Michelle A Ozbun; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.